650 related articles for article (PubMed ID: 32754161)
1. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
2. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors.
Trezza A; Iovinelli D; Santucci A; Prischi F; Spiga O
Sci Rep; 2020 Aug; 10(1):13866. PubMed ID: 32807895
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
4.
Br B; Damle H; Ganju S; Damle L
F1000Res; 2020; 9():663. PubMed ID: 32765844
[No Abstract] [Full Text] [Related]
5. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
6. The Utility of Native MS for Understanding the Mechanism of Action of Repurposed Therapeutics in COVID-19: Heparin as a Disruptor of the SARS-CoV-2 Interaction with Its Host Cell Receptor.
Yang Y; Du Y; Kaltashov IA
Anal Chem; 2020 Aug; 92(16):10930-10934. PubMed ID: 32678978
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
8. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.
Yang J; Petitjean SJL; Koehler M; Zhang Q; Dumitru AC; Chen W; Derclaye S; Vincent SP; Soumillion P; Alsteens D
Nat Commun; 2020 Sep; 11(1):4541. PubMed ID: 32917884
[TBL] [Abstract][Full Text] [Related]
9. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
Sharifkashani S; Bafrani MA; Khaboushan AS; Pirzadeh M; Kheirandish A; Yavarpour Bali H; Hessami A; Saghazadeh A; Rezaei N
Eur J Pharmacol; 2020 Oct; 884():173455. PubMed ID: 32745604
[TBL] [Abstract][Full Text] [Related]
11. Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of combating Covid-19 infectivity.
Drew ED; Janes RW
BMC Mol Cell Biol; 2020 Jul; 21(1):49. PubMed ID: 32611313
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of receptor recognition by SARS-CoV-2.
Shang J; Ye G; Shi K; Wan Y; Luo C; Aihara H; Geng Q; Auerbach A; Li F
Nature; 2020 May; 581(7807):221-224. PubMed ID: 32225175
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates.
Alazmi M; Motwalli O
J Mol Model; 2020 Nov; 26(12):338. PubMed ID: 33175236
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
15. Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment.
Teralı K; Baddal B; Gülcan HO
J Mol Graph Model; 2020 Nov; 100():107697. PubMed ID: 32739642
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.
Clausen TM; Sandoval DR; Spliid CB; Pihl J; Perrett HR; Painter CD; Narayanan A; Majowicz SA; Kwong EM; McVicar RN; Thacker BE; Glass CA; Yang Z; Torres JL; Golden GJ; Bartels PL; Porell RN; Garretson AF; Laubach L; Feldman J; Yin X; Pu Y; Hauser BM; Caradonna TM; Kellman BP; Martino C; Gordts PLSM; Chanda SK; Schmidt AG; Godula K; Leibel SL; Jose J; Corbett KD; Ward AB; Carlin AF; Esko JD
Cell; 2020 Nov; 183(4):1043-1057.e15. PubMed ID: 32970989
[TBL] [Abstract][Full Text] [Related]
17. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
Romeo A; Iacovelli F; Falconi M
Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
[TBL] [Abstract][Full Text] [Related]
18. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
19. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
